News - ANAVEX

View all Alzheimer's Disease Anavex2-73 Events News Releases PIPELINE Press Uncategorized

2016 Epilepsy Pipeline Conference

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016

18th Annual BIO CEO & Investor Conference

Anavex Announces Positive Dose-Response Data for ANAVEX 2-73 in Alzheimer’s Disease Patients

New Alzheimer’s Drug ANAVEX 2-73: A Phase 2a Study, Clinical Safety, Tolerability and Maximum Tolerated Dose finding in mild-to-moderate Alzheimer’s Patients.

Anavex Issues Statement Addressing Recent Press Releases by Law Firms

Anavex Announces Fiscal 2015 Year-End Financial Results

Novel Anti-Seizure Compound ANAVEX 2-73 a Sigma-1 Receptor Agonist in Multiple Seizure Models.

American Epilepsy Society Annual Meeting

Third Annual MHPAEA Business Roundtable